JP2023544143A - 抗クローディン18.2および抗cd3二重特異性抗体およびその使用 - Google Patents

抗クローディン18.2および抗cd3二重特異性抗体およびその使用 Download PDF

Info

Publication number
JP2023544143A
JP2023544143A JP2023519492A JP2023519492A JP2023544143A JP 2023544143 A JP2023544143 A JP 2023544143A JP 2023519492 A JP2023519492 A JP 2023519492A JP 2023519492 A JP2023519492 A JP 2023519492A JP 2023544143 A JP2023544143 A JP 2023544143A
Authority
JP
Japan
Prior art keywords
amino acid
seq
antibody
acid sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2023519492A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544143A5 (cg-RX-API-DMAC7.html
Inventor
ショアイシアン チョウ
チョー コアン
ウェイウェイ ウー
ヤーロン カオ
Original Assignee
イノベント バイオロジクス(シンガポール)プライベート リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イノベント バイオロジクス(シンガポール)プライベート リミティド filed Critical イノベント バイオロジクス(シンガポール)プライベート リミティド
Publication of JP2023544143A publication Critical patent/JP2023544143A/ja
Publication of JP2023544143A5 publication Critical patent/JP2023544143A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023519492A 2020-09-29 2021-09-28 抗クローディン18.2および抗cd3二重特異性抗体およびその使用 Ceased JP2023544143A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011054428 2020-09-29
CN202011054428.6 2020-09-29
PCT/CN2021/121286 WO2022068810A1 (zh) 2020-09-29 2021-09-28 抗Claudin18.2和CD3的双特异性抗体以及其用途

Publications (2)

Publication Number Publication Date
JP2023544143A true JP2023544143A (ja) 2023-10-20
JP2023544143A5 JP2023544143A5 (cg-RX-API-DMAC7.html) 2024-10-07

Family

ID=80949663

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519492A Ceased JP2023544143A (ja) 2020-09-29 2021-09-28 抗クローディン18.2および抗cd3二重特異性抗体およびその使用

Country Status (9)

Country Link
US (1) US20230357389A1 (cg-RX-API-DMAC7.html)
EP (1) EP4223778A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023544143A (cg-RX-API-DMAC7.html)
KR (1) KR20230079165A (cg-RX-API-DMAC7.html)
CN (1) CN116323676A (cg-RX-API-DMAC7.html)
AU (1) AU2021352532B2 (cg-RX-API-DMAC7.html)
CA (1) CA3200865A1 (cg-RX-API-DMAC7.html)
TW (1) TWI837517B (cg-RX-API-DMAC7.html)
WO (1) WO2022068810A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023245103A1 (en) * 2022-03-28 2024-10-24 Fortvita Biologics (Singapore) Pte. Ltd. Preparations containing anti-claudin18.2/cd3 bispecific antibody, preparation method therefor and use thereof.
CN117229398A (zh) * 2022-06-15 2023-12-15 中山康方生物医药有限公司 抗cldn18.2抗体、其药物组合物及用途
KR20240101987A (ko) * 2022-12-23 2024-07-03 주식회사 와이바이오로직스 클라우딘-18.2에 특이적으로 결합하는 단클론항체 및 이의 용도
CN116813782B (zh) * 2023-08-10 2024-01-23 北京百普赛斯生物科技股份有限公司 一种Claudin-18.2特异性抗体及其应用
WO2025162454A1 (zh) * 2024-02-02 2025-08-07 北京昌平实验室 双特异性抗体和细胞因子融合蛋白及其应用
CN120829517A (zh) * 2024-04-22 2025-10-24 鲁南新时代生物技术有限公司 抗cldn18.2/cd3双特异性抗体及用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016500059A (ja) * 2012-11-13 2016-01-07 バイオエヌテック アーゲーBioNTech AG クローディンを発現するガン疾患を処置するための剤
JP2020018298A (ja) * 2018-08-03 2020-02-06 アムジェン リサーチ (ミュニック) ゲゼルシャフト ミット ベシュレンクテル ハフツング Cldn18.2及びcd3に対する抗体コンストラクト
JP2020505929A (ja) * 2017-02-02 2020-02-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 抗体ドメインの好ましい対形成
JP2020508054A (ja) * 2017-02-17 2020-03-19 デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. 抗タウ抗体及びその使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
EP2920209B1 (en) * 2012-11-13 2020-08-05 BioNTech SE Agents for treatment of claudin expressing cancer diseases
BR112015010817A8 (pt) * 2012-11-13 2018-01-23 Genentech Inc anticorpos anti-hemaglutinina isolado, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico isolado, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina
CN106589127A (zh) * 2015-10-16 2017-04-26 钜川生物医药 一种pcsk9抗体及其制备方法和应用
WO2018054484A1 (en) * 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
EP3409322A1 (en) * 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
CN111247171A (zh) * 2017-10-14 2020-06-05 西托姆克斯治疗公司 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
CA3098910A1 (en) * 2018-05-01 2019-11-07 Ambrx, Inc. A method for optimizing antibody expression
EP3808376A4 (en) * 2018-06-17 2021-09-01 L&L Biopharma Co., Ltd. CLDN18.2 ANTIBODY, BISPECIFIC ANTIBODY, ADC AND CAR, AND APPLICATIONS THEREOF

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016500059A (ja) * 2012-11-13 2016-01-07 バイオエヌテック アーゲーBioNTech AG クローディンを発現するガン疾患を処置するための剤
JP2020505929A (ja) * 2017-02-02 2020-02-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 抗体ドメインの好ましい対形成
JP2020508054A (ja) * 2017-02-17 2020-03-19 デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. 抗タウ抗体及びその使用方法
JP2020018298A (ja) * 2018-08-03 2020-02-06 アムジェン リサーチ (ミュニック) ゲゼルシャフト ミット ベシュレンクテル ハフツング Cldn18.2及びcd3に対する抗体コンストラクト

Also Published As

Publication number Publication date
AU2021352532A1 (en) 2023-05-25
CA3200865A1 (en) 2022-04-07
AU2021352532B2 (en) 2026-01-15
CN116323676A (zh) 2023-06-23
WO2022068810A1 (zh) 2022-04-07
TW202216783A (zh) 2022-05-01
TWI837517B (zh) 2024-04-01
US20230357389A1 (en) 2023-11-09
KR20230079165A (ko) 2023-06-05
EP4223778A1 (en) 2023-08-09
AU2021352532A9 (en) 2025-03-13
EP4223778A4 (en) 2024-11-06

Similar Documents

Publication Publication Date Title
TWI883044B (zh) 使用her3抗原結合分子的癌症之治療及預防
JP7842703B2 (ja) 抗Claudin18.2抗体およびその使用
KR102593409B1 (ko) Her3 항원 결합 분자
CN116261590B (zh) 抗cd3抗体以及其用途
TWI793395B (zh) 結合pd-l1和ox40的雙特異性抗體
KR20210109520A (ko) 항체 및 이의 용도
TWI837517B (zh) 抗claudin 18.2和cd3的雙特異性抗體以及其用途
WO2020114478A1 (zh) Cd3抗体及其药物用途
JP2025522557A (ja) Egfrおよびb7-h3に結合する二重特異性抗体
JP7538131B2 (ja) 抗cd79b抗体、その抗原結合フラグメントおよびそれらの医薬用途
JP2025508317A (ja) 抗cd3及び抗cd20二重特異性抗体、並びにその使用
TW202214694A (zh) 結合tnfr2的抗體及其用途
CA3259098A1 (en) ANTIBODIES AND THEIR USES
TW202400662A (zh) 結合pd-l1和cldn18.2的抗體及其用途
CN110606892B (zh) 一种高亲和力高生物活性的lag-3抗体及其应用
HK40075856A (en) Her3 antigen-binding molecules
KR20260062948A (ko) Ctla4/tigit 결합 단백질 및 이의 의학적 용도
CN118846036A (zh) 一种包含特异性结合cd3和muc16的双特异性抗体的药物组合
CN120329439A (zh) 一种单克隆抗体及其应用
HK40083793A (en) Anti-claudin18.2 antibody and use thereof

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250812

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251112

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260113

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20260526